OBJECTIVES The aim of this study was to develop a risk index specific to patients on mechanical circulatory support that accurately predicts 1-year mortality after orthotopic heart transplantation using the United Network for Organ Sharing database.
A lthough bridge to transplantation (BTT) with mechanical circulatory support (MCS) has become increasingly prevalent (1) (2) (3) (4) , several studies evaluating the role of destination therapy have demonstrated acceptable mid-and long-term outcomes (5) (6) (7) (8) . Therefore, the decision to proceed with orthotopic heart transplantation (OHT) after a period of mechanical support is not straightforward.
Furthermore, current models do not sufficiently predict the risk for mortality in these bridged cohorts (9) . The sample was then randomly divided into an 80% model derivation cohort and a 20% validation cohort.
MCS was defined as having an intracorporeal device at the time of transplantation and was stratified by anatomic position (left ventricular assist device
[LVAD], right ventricular assist device, biventricular assist device, total artificial heart, or unspecified).
Survival time began at the date of transplantation.
The primary outcome was 1-year mortality; secondary endpoints included 90-day and 3-year mortality as well as overall survival time. Standard UNOS variables and definitions were used. Prior dialysis included any dialysis requirement at or since listing.
Recent infection was any infection treated within the 2 weeks before transplantation.
ANALYSIS. The dataset contained 680 variables, including both donor and recipient data. All plausible variables for predicting 1-year mortality were evaluated using univariate logistic regression in the derivation sample. The multivariate regression model was built in a hierarchical fashion with variable inclusion on the basis of 3 criteria: 1) variables were included if they had previously been found to be significant in relevant published research (10,11);
2) variables were included if they were hypothesized Kaplan-Meier survival curves stratified by risk grouping, and differences in risk groupings were tested using the log-rank test for survival equality.
RESULTS
PATIENT DEMOGRAPHICS. A total of 6,036 patients constituted the overall sample. The mean age was 51.2 AE 12.7 years, and 18.3% of the cohort were women Table 1) .
VARIABLES SELECTED FROM THE DERIVATION
COHORT.
Of the approximately 50 variables that were screened in univariate logistic regression, 20
were at least modestly associated with 1-year mortality and were candidates for inclusion in the final donor glomerular filtration rate (GFR) ( Table 2) .
Complete data were available to calculate scores for In both the derivation and validation cohorts, predicted mortality conformed to observed mortality up to a score of approximately 40, at which small sample size and outliers skewed the relationship between predicted and observed 1-year mortality ( Figure 3 ).
We also explored stratification of patients into high-, medium-, and low-risk groups on the basis of clinically meaningful differences in expected mortality.
Patients were separated into 3 groups: score ranges of 0 to 10, 11 to 20, and >20. potentially move from high-risk to low-risk groups with alternative organ selection. 93.5%, pairwise log-rank p < 0.001). Findings were similar in the test group, with the high-risk group having 19.6% lower cumulative survival at 1 year than the low-risk group (73.3% vs. 92.9%, pairwise logrank p < 0.001).
DISCUSSION
In the first study to model 1-year mortality risk in patients bridging with MCS to OHT, we found that the TRIP-MCS, a simple additive score, accurately predicted risk for 1-year mortality after transplantation. promote all but the lowest risk patients from low-to medium-risk groups or from medium-to high-risk groups, and each subsequent risk group represents a near doubling of predicted mortality at 1 year.
Last, we note variables that failed to predict mortality risk in our model.
We originally hypothesized that patients with ventricular assist devices were more likely to be sensitized because of previous transfusions associated with device implantation (17) and that this would increase 1-year mortality, but neither transfusions nor percentage reactive antigens added significant explanatory power in our model. We also found that in the setting of MCS and accounting for device type, the etiology of the patient's heart failure did not improve the model. Observed versus expected (predicted) 1-year mortality with 95% confidence interval of the predicted mortality (dotted lines) for both derivation and validation cohorts. Locally weighted best fit lines for the observed data are also plotted (dashed lines). The size of the observed mortality marker reflects the number of patients with that score. Average predicted 1-year mortality by score risk groups in the derivation and validation cohorts, with 95% confidence intervals.
Mod. ¼ moderate. *p < 0.001. shah@vanderbilt.edu.
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